0000886744 false 12/31 0000886744 2021-05-10 2021-05-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 11, 2021

GERON CORPORATION
(Exact name of registrant as specified in its charter)

Delaware 000-20859 75-2287752
(State or other jurisdiction of
incorporation)
(Commission File Number) (IRS Employer Identification No.)

919 E. HILLSDALE BLVD., SUITE 250
FOSTER CITY, california 94404

(Address of principal executive offices, including zip code)

(650) 473-7700
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value GERN The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


                  
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 11, 2021, Geron Corporation (the “Company”) held its 2021 Annual Meeting of Stockholders in a virtual meeting format, pursuant to notice duly given (the “2021 Annual Meeting”). At the 2021 Annual Meeting, the Company’s stockholders also approved an amendment to the Geron Corporation 2018 Equity Incentive Plan (the “2018 Plan”) to, among other items, increase the shares issuable thereunder by 12,500,000 shares of the Company’s common stock. The amendment to 2018 Plan was adopted by the Board of Directors of the Company (the “Board”) on February 2, 2021, subject to stockholder approval, and became effective when approved by the Company’s stockholders on May 11, 2021.

The 2018 Plan was initially adopted by the Board in March 2018 and approved by the stockholders in May 2018. The terms of the 2018 Plan provide for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, other stock awards, and performance awards that may be settled in cash, stock, or other property. Upon adoption, the 2018 Plan had an initial share reserve of 10,000,000 shares of common stock. The aggregate number of shares of the Company’s common stock issuable under the 2018 Plan also included, as of the effective date of the 2018 Plan: (i) 2,895,419 unallocated shares that were remaining available for the grant of awards under the 2011 Equity Incentive Plan (the “2011 Plan”) as of the effective date of the 2018 Plan; (ii) certain shares subject to outstanding awards granted under the 2011 Plan and the 1992 Stock Option Plan, the 1996 Directors’ Stock Option Plan and the Amended and Restated 2002 Equity Incentive Plan (collectively, the “Prior Plans”) that may become available for grant under the 2018 Plan as such shares become available from time to time; and as of May 11, 2021 (iii) 5,700,000 shares approved by stockholders at the 2020 Annual Meeting of Stockholders; and (iv) 12,500,000 shares approved by stockholders at the 2021 Annual Meeting. “Returning Shares” means shares subject to outstanding stock awards granted under the Prior Plans that, from and after the effective date, (i) expire or terminate for any reason prior to exercise or settlement, (ii) are forfeited, cancelled or otherwise returned to the Company because of the failure to meet a contingency or condition required for the vesting of such shares, or (iii) other than with respect to outstanding stock options and stock appreciation rights granted under the Prior Plans with an exercise or strike price of at least 100% of the fair market value of the underlying Company common stock on the date of grant, are reacquired or withheld (or not issued) by the Company to satisfy a tax withholding obligation in connection with a stock award. Eligible participants under the 2018 Plan include the Company’s employees, consultants and directors, including the Company’s executive officers.

A more detailed summary of the material features of the 2018 Plan, including the terms of stock option grants thereunder, is set forth in the Company’s definitive proxy statement for the 2021 Annual Meeting filed with the SEC on March 22, 2021 (the “Proxy Statement”). That summary and the foregoing description are qualified in their entirety by reference to the text of the 2018 Plan, a copy of which is incorporated by reference as Exhibit 10.1 hereto.
                  
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

At the 2021 Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s Common Stock from 450,000,000 to 675,000,000 shares. The increase in the authorized number of shares of the Company’s Common Stock was effected pursuant to a Certificate of Amendment of the Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on May 12, 2021 and was effective as of such date. The foregoing description of the Amendment is qualified in its entirety by the Certificate of Amendment, which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.
                  
Only stockholders of record as of the close of business on March 18, 2021, the record date for the 2021 Annual Meeting, were entitled to vote at the 2021 Annual Meeting. As of March 18, 2021, 318,530,740 shares of common stock of the Company were outstanding and entitled to vote at the 2021 Annual Meeting, of which 211,609,017 shares of common stock of the Company were represented, in person or by proxy, constituting a quorum. The final results of the stockholder vote on each proposal brought before the 2021 Annual Meeting are as follows:

1


             

(a)

Proposal 1. Each of the two (2) nominees to hold office as Class I members of the Board of Directors to serve for a three-year term expiring at the Company’s 2024 annual meeting of stockholders was elected based upon the following votes:

     
             Name of Director Nominee Votes In Favor Votes Withheld Broker Non-Votes
John A. Scarlett, M.D. 107,856,538 19,085,899 84,666,580
Robert J. Spiegel, M.D., FACP 91,904,110 35,038,327 84,666,580
             

(b)

Proposal 2. The amendment to the Company’s Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from 450,000,000 to 675,000,000 shares was approved based upon the following votes:

     
             Votes For Votes Against Abstentions Broker Non-Votes
177,574,925 30,711,051 3,323,041 0
             

(c)

Proposal 3. The amendment to the Company’s 2018 Equity Incentive Plan to, among other items, increase the total shares issuable thereunder by 12,500,000 shares of common stock hereby was approved based upon the following votes:

     
             Votes For Votes Against Abstentions Broker Non-Votes
102,736,738 23,385,455 820,244 84,666,580
             

(d)

Proposal 4. The non-binding advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the Proxy Statement was approved based upon the following votes:

     
             Votes For Votes Against Abstentions Broker Non-Votes
101,688,287 23,676,742 1,577,408 84,666,580
             

(e)

Proposal 5. The selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 was ratified based upon the following votes:

     
             Votes For Votes Against Abstentions Broker Non-Votes
206,481,787 4,001,901 1,125,329 0
 
Item 9.01        Financial Statements and Exhibits.
     
(d) Exhibits.
     
                     Exhibit No.            Description
3.1 Certificate of Amendment of the Restated Certificate of Incorporation
10.1 2018 Equity Incentive Plan, as amended
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

2


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GERON CORPORATION
 
Date: May 13, 2021 By:      /s/ Stephen N. Rosenfield     
Name:    Stephen N. Rosenfield
Title: Executive Vice President,
Chief Legal Officer and
Corporate Secretary

3


Geron (NASDAQ:GERN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Geron Charts.
Geron (NASDAQ:GERN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Geron Charts.